Nine-month interim report May - January 2010/11

Nine-month interim report May - January 2010/11

Order bookings increased 10* percent to SEK 6,041 M (5,705).

Net sales rose 14* percent to SEK 5,328 M (4,835).

Operating profit increased to SEK 751 M (553).

Net income rose to SEK 500 M (358).

Earnings per share after dilution improved to SEK 5.30 (3.91).

Cash flow from operating activities amounted to SEK 460 M (589). Cash
flow after investments was SEK 142 M (527), including acquisitions of
SEK -255 M (0). 

For fiscal year 2010/11, net sales is expected to grow by 12-14 percent
in local currency. Operating profit in SEK is expected to grow by 16-20
percent.

Table included in attached PDF file
* Compared to last fiscal year at unchanged exchange rates.

President and CEO Tomas Puusepp comments  

I am very pleased with Elekta's solid performance in the first nine
months of fiscal year 2010/11. Order bookings increased by 10 percent
based on unchanged exchange rates.
Operating profit rose by 36 percent to SEK 751 M (553) with an operating
margin improvement to 14 percent (11).

Order intake for the nine-month period was particularly strong in Region
North and South America, helped by a strong third quarter in the North
American market and a positive development in Brazil. In the Asia
Pacific region, China, India and Australia represented the strongest
growth markets. Demand in Europe, Middle East and Africa showed a mixed
picture. Eastern Europe, Russia and Italy reported continued solid
growth while activity was lower in the UK and in the Nordic countries.

There may be quarterly fluctuations in demand in the respective regions.
However, we expect sustainable growth rates for region Europe, Middle
East and Africa as well as for North America at mid to high single digit
levels, and double digit growth rates for the Asia Pacific region.

The need for cancer care is growing world wide. Elekta is market leader
in emerging markets, where the demand for clinical solutions like
Elekta's is particularly strong. We continue to make cancer care
available to more people around the world through geographical
expansion. Key success factors are our long term customer relations, our
innovative capabilities and our commitment to the highest level of
service and customer care.

Elekta provides world leading solutions in image-guided radiation
therapy, stereotactic radiosurgery and oncology software in
collaboration with the foremost universities and hospitals worldwide.
There is an increasing interest for stereotactic radiosurgery and
stereotactic radiotherapy for the treatment of cancer and multiple
metastatic tumors.

With good visibility for the remainder of the fiscal year, Elekta's
financial outlook for the fiscal year 2010/11 has been changed.  Net
sales is expected to grow by 12-14 percent in local currency. Operating
profit in SEK is expected to grow by 16-20 percent.  

Tomas Puusepp
President and CEO